retatrutide timeline dose schedule: complete week-by-week titration guide Retatrutide vs. semaglutide: A head-to-head

Reduction in Risk Across Fourteen Obesity-Related Cancers A large observational study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, involving more than 170,000 patients with diabetes and obesity, found that GLP-1 receptor agonists were associated with a modest but statistically meaningful reduction in the incidence of 14 obesity-related cancers , with colorectal cancer demonstrating particularly favourable outcomes when compared to patients receiving DPP-4 inhibitors

Research suggests the peptide may interact with fundamental cellular processes that govern how cells age and repair themselves over time

doi: 10.3390/jcm8010045, 68

Keenan, E

10.1016/j.cell.2008.07.041 127 ParkI